By Daniella Parra
Promontory Therapeutics Inc. completed enrollment of 109 late-stage metastatic castration-resistant prostate cancer patients for its Phase 2 trial of PT-112, which assesses its efficacy in patients who have undergone prior treatments, the company said.
PT-112 is a promising small-molecule conjugate of pyrophosphate, notable for its tolerability and ability to induce immunogenic cell death and is potential as a treatment option for mCRPC patients who have exhausted other therapies, Promontory said.
“This clinical trial is the largest study to date of PT-112 and will establish the optimal dose in line with the FDA’s Project Optimus, as well as proof of concept in our late-line mCRPC patient population,” said Promontory Therapeutics Chief Medical Officer Johan Baeck, MD.
Contact:
executives-edge.com
Editor@executives-edge.com
